These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 4679645)
1. Antilipemic drugs and the position of the FDA. Finkel MJ Adv Exp Med Biol; 1972; 26(0):263-5. PubMed ID: 4679645 [No Abstract] [Full Text] [Related]
2. Letter: The UGDP scandal and cover-up. Moss JM JAMA; 1975 May; 232(8):806-8. PubMed ID: 1173182 [No Abstract] [Full Text] [Related]
3. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease. Temple R Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896 [No Abstract] [Full Text] [Related]
4. What kinds of studies should be required to probe efficacy and safety of drugs in special populations? LaRosa JC; Sneider GB; Boyle C Am J Cardiol; 1998 Apr; 81(8A):84F-87F. PubMed ID: 9604921 [No Abstract] [Full Text] [Related]
5. The FDA and hypoglycemic drugs. Davidson JK JAMA; 1975 May; 232(8):853-5. PubMed ID: 1091764 [No Abstract] [Full Text] [Related]
6. The oral hypoglycemic controversy. Stay as sweet as you are. Gregory DR Leg Aspects Med Pract; 1979 Mar; 7(3):16-9. PubMed ID: 106193 [No Abstract] [Full Text] [Related]
8. The role of the central clinical laboratory in the development of drugs for the treatment of cardiovascular disease by the modification of lipoprotein concentrations. Cole TG Am J Cardiol; 1998 Apr; 81(8A):75F-77F. PubMed ID: 9604917 [No Abstract] [Full Text] [Related]
9. Regulatory concerns at various phases of drug development. Aurecchia S; Orloff D; Sobel S Am J Cardiol; 1998 Apr; 81(8A):2F-4F. PubMed ID: 9604895 [No Abstract] [Full Text] [Related]
10. Editorial: Let's stop the Donnybrook. A perspective on the UGDP-Biometric Society Study. Moser RH JAMA; 1975 Mar; 231(12):1274-6. PubMed ID: 1172958 [No Abstract] [Full Text] [Related]
11. Potentiation of hypoglycemic effect of chlorpropamide and phenfromin by halofenate. Kudzma DJ; Friedberg SJ Diabetes; 1977 Apr; 26(4):291-5. PubMed ID: 321288 [TBL] [Abstract][Full Text] [Related]
12. Medical watergate? Critics charge a cover-up at HEW of faulty research. Born RC Barrons; 1978 Oct; 58(43):9-10, 17-8. PubMed ID: 10238964 [No Abstract] [Full Text] [Related]
13. Tolbutamide: more questions than answers. Barclay WR JAMA; 1971 Jan; 215(1):108-9. PubMed ID: 5107341 [No Abstract] [Full Text] [Related]
14. Status of problem of usage of tolbutamide. Preliminary statements. Diabetes; 1970 Jun; 19(6):467-8. PubMed ID: 5467867 [No Abstract] [Full Text] [Related]
15. FDA considerations regarding new hypolipidemic agents. Finkel MJ Lipids; 1977 Jan; 12(1):64-5. PubMed ID: 834124 [TBL] [Abstract][Full Text] [Related]
16. [Use of tolbutamide in diabetes and pregnancy]. Villanueva Gasca A; María García L; López Villegas J; Núñez E Ginecol Obstet Mex; 1975 Aug; 38(226):133-7. PubMed ID: 1175987 [No Abstract] [Full Text] [Related]
17. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Seltzer HS Diabetes; 1972 Sep; 21(9):976-9. PubMed ID: 5055722 [No Abstract] [Full Text] [Related]